恒瑞医药子公司SHR—8068注射液等三款药物获临床试验批准

Core Viewpoint - Heng Rui Medicine has received approval for clinical trials of three new drug candidates, indicating a significant advancement in its oncology pipeline [1] Group 1: Company Developments - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., and Shanghai Shengdi Medicine Co., Ltd. have received clinical trial approval from the National Medical Products Administration for SHR-8068 injection, Adebali monoclonal antibody injection, and Bevacizumab injection [1] - SHR-8068 injection is a fully human anti-CTLA-4 monoclonal antibody aimed at enhancing anti-tumor immune effects [1] - Adebali monoclonal antibody injection is a humanized anti-PD-L1 monoclonal antibody developed by Heng Rui Medicine, designed to block the PD-1/PD-L1 pathway, thereby reactivating the immune system's anti-tumor activity [1] - Bevacizumab is a humanized anti-VEGF monoclonal antibody, which is also part of Heng Rui Medicine's oncology treatment offerings [1]